Scholar Rock Holding Corp. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Scholar Rock Holding Corp. on December 2, 2025. The filing addresses Item 8.01 (Other Events) concerning regulatory developments affecting the Company's manufacturing partner, Catalent Indiana, LLC (part of Novo Nordisk), and the anticipated timeline for the launch of the Company's drug candidate, apitegromab.
Key Financial Metrics
The filing text does not provide specific financial data, including revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on regulatory and operational events.
Material Changes and Events
- FDA Inspection Outcome: The U.S. Food and Drug Administration (FDA) classified the Catalent Indiana facility as "official action indicated" following a Form FDA 483 issued on July 14, 2025.
- Warning Letter: Catalent Indiana has received a formal warning letter from the FDA regarding the inspection findings.
- Resolution Status: Catalent Indiana is actively working with the FDA to resolve the outstanding issues cited in the warning letter.
Guidance, Outlook, and Risks
Based on a Type A Meeting held on November 12, 2025, and current information from Catalent Indiana, the Company continues to anticipate the following:
- Resubmission of its biologics license application (BLA) for apitegromab.
- U.S. launch of apitegromab for the treatment of spinal muscular atrophy (SMA) in 2026, contingent upon approval.
Risks and Contingencies: The filing includes standard forward-looking statement disclaimers. Actual results may differ materially due to uncertainties regarding the FDA's actions, the speed of Catalent Indiana's remediation, and regulatory approval timelines. The Company references risk factors detailed in its most recent Form 10-Q for the quarter ended September 30, 2025.
Investor Verification Checklist
- Verify the specific deficiencies cited in the FDA warning letter to Catalent Indiana.
- Monitor the timeline for the resubmission of the apitegromab biologics license application.
- Review the Company's most recent Form 10-Q (ended September 30, 2025) for detailed financial liquidity and risk factors.
- Track updates on the FDA's "official action indicated" classification status for the manufacturing facility.